Navigation Links
Symic Biomedical Appoints Kamal Egodage, Ph.D., MBA, VP of Development & Manufacturing and Grace Wong-Sarad, VP and Controller
Date:11/5/2015

SAN FRANCISCO, Nov. 5, 2015 /PRNewswire/ -- Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target the extracellular matrix (ECM), today announced the appointment of Kamal Egodage, Ph.D., MBA, as Vice President of Development & Manufacturing and Grace Wong-Sarad as Vice President and Controller.

"We have just entered a critical stage for the company with the initiation of the SHIELD trial for our lead vascular candidate, SB-030, and the broad expertise of both Kamal and Grace will be invaluable as we focus on the achievement of our next milestones, including the selection of our next pipeline candidate," said Ken Horne, Chief Executive Officer of Symic Biomedical. "We are laying the foundation for growth with the expansion of our management team as we advance our pipeline targeting the extracellular matrix."

Dr. Egodage has 20 years of biotherapeutics development experience in both in the U.S. and Europe. Prior to joining Symic, he held leadership positions with increasing responsibility in Novartis, Eli Lilly, Pharmacia and Monsanto in the areas of biologics research and development (R&D), strategy and business development. Dr. Egodage has contributed to numerous regulatory submissions in multiple therapeutic areas, and, in his recent biologics strategy and business development role at Novartis, he led R&D teams in the areas of cardiovascular and metabolism, oncology and autoimmunity, transplantation and inflammation. Dr. Egodage received his Ph.D. in bioanalytical chemistry from University of Kansas and earned an MBA from the Kellogg School of Management and Otto Beisheim School of Management in Germany.

Ms. Wong-Sarad has more than 20 years combined experience in biotechnology finance and audit and assurance. She previously served as Senior Director, Corporate Controller, at Hyperion Therapeutics, where she was a key team member responsible for the company's successful IPO in 2012 and a secondary offering in 2013. During her time at Hyperion she led the finance and accounting function, revenue reporting, SEC reporting and tax, among other responsibilities. Prior to Hyperion, Ms. Wong-Sarad held management positions of increasing responsibility at KPMG in Thailand and in the U.S., and at Ernst & Young Philippines (SGV & Co.). She is a certified public accountant and holds a Bachelor of Science in accountancy from San Pedro College of Business in the Philippines.

About Symic Biomedical

Symic Biomedical is a clinical-stage biotherapeutics company developing a pipeline of products targeting the extracellular matrix (ECM). Symic's proprietary compounds function like proteoglycans, important structural and functional macromolecules native to the ECM, which is the non-cellular component of tissues that is critical for healthy tissue function. Components of the ECM, particularly proteoglycans, play a critical role in healing following injury and in chronic diseases. SB-030 is Symic's lead compound under evaluation in the Phase 1/2 clinical study for vascular endothelial injury.

Symic Biomedical is based in San Francisco. For additional information, please visit the company's website at http://www.symic.bio or follow us on Twitter at www.twitter.com/symicbio and LinkedIn at www.linkedin.com/company/symic-bio/.

Media Contacts

David Schull or Lena Evans
Russo Partners, LLC
(212) 845-4271
(212) 845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com


'/>"/>
SOURCE Symic Biomedical
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Symic Biomedical Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial
2. Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD
3. Symic Biomedical Announces Appointment of Barbara Yanni and Bill Newell as Independent Directors to its Board
4. Protein Photonics Special Section in Journal of Biomedical Optics Honors Nobel Laureate Osamu Shimomura
5. Kobe Showcases Biomedical Innovation Cluster to Foreign Correspondents
6. G2 Intelligence and Arizona State Universitys International School of Biomedical Diagnostics Announce Diagnostic Research and Education Alliance
7. Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020
8. Mexico Biomedical Sensors Market Report 2015-2020
9. Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020
10. Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020
11. Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):